Vertex Pharmaceuticals presented updated 48‑week data from the RUBY‑3 Phase 1/2 study at the American Society of Nephrology Kidney Week on November 9, 2025. The data show a 64% reduction in proteinuria in IgA nephropathy and an 82% reduction in primary membranous nephropathy, with estimated glomerular filtration rate stabilization in both groups.
The study also reported high rates of clinical remission: 53% of IgAN patients and 40% of pMN patients achieved remission, and 90% of IgAN patients had hematuria resolution. Safety was favorable, with no serious adverse events related to povetacicept.
Vertex plans to submit a rolling Biologics License Application for povetacicept in IgAN this year and has received Fast Track designation for pMN. The data support the drug’s potential to become the first disease‑modifying therapy for these kidney disorders, offering a new revenue stream and further diversifying Vertex’s portfolio beyond cystic fibrosis.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.